| scholarly article | Q13442814 |
| P2093 | author name string | Patrick J Medina | |
| Susan Goodin | |||
| P433 | issue | 8 | |
| P304 | page(s) | 1426-1447 | |
| P577 | publication date | 2008-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases | |
| P478 | volume | 30 |
| Q64258132 | (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo |
| Q33629947 | A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. |
| Q36290627 | A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids |
| Q43120670 | A validated RP-HPLC method for the estimation of lapatinib in tablet dosage form using gemcitabine hydrochloride as an internal standard |
| Q39118167 | An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry |
| Q35237773 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole |
| Q38908654 | Antimalarial activity of kinase inhibitor, nilotinib, in vitro and in vivo |
| Q37976288 | Array-based pharmacogenomics of molecular-targeted therapies in oncology. |
| Q34260243 | Assay of lapatinib in murine models of cigarette smoke carcinogenesis. |
| Q39136014 | Autophagy stimulates apoptosis in HER2‐overexpressing breast cancers treated by lapatinib |
| Q37983260 | Cancer and Age: General Considerations |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q37873453 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. |
| Q37522017 | Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs |
| Q36139333 | Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. |
| Q30438089 | Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer |
| Q33721983 | Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis |
| Q64998055 | Cytotoxic Effect of Paclitaxel and Lapatinib Co-Delivered in Polylactide-co-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells. |
| Q38137253 | Design and evaluation of radiolabeled tracers for tumor imaging |
| Q53160975 | Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products |
| Q46306752 | Development and Validation of a High-Performance Liquid Chromatography Ultraviolet Method for Lapatinib Quantification in Human Plasma |
| Q36384340 | Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea |
| Q33999288 | Development of the rat model of lapatinib-induced diarrhoea. |
| Q39733170 | Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. |
| Q64097515 | Drug sensitivity prediction with high-dimensional mixture regression |
| Q38225680 | Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective |
| Q39091696 | Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation |
| Q39307190 | EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship |
| Q38240998 | Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer |
| Q34626878 | Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses |
| Q54293320 | Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization. |
| Q30457869 | ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular Schwannomas |
| Q37668848 | ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases |
| Q45253639 | Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening |
| Q38238613 | Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer |
| Q36414193 | Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation |
| Q37326863 | Future of targeted agents in metastatic colorectal cancer |
| Q36657315 | Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression |
| Q39687743 | H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 |
| Q37746163 | HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E |
| Q27026178 | HER2 as a therapeutic target in head and neck squamous cell carcinoma |
| Q38004902 | HER2-Positive DTCs/CTCs in Breast Cancer |
| Q92432175 | HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis |
| Q28477481 | Identification of Potent EGFR Inhibitors from TCM Database@Taiwan |
| Q38457923 | Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis |
| Q30383865 | Impact of germline and somatic missense variations on drug binding sites |
| Q38735063 | In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles. |
| Q39186813 | Incorporation of Lapatinib Into Lipoprotein-Like Nanoparticles with Enhanced Water Solubility and Anti-Tumor Effect in Breast Cancer |
| Q35892045 | Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative |
| Q51137512 | Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. |
| Q34788890 | Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer |
| Q37692439 | Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab |
| Q38130485 | Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy |
| Q55091931 | Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. |
| Q97644226 | Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells |
| Q35913209 | Lapatinib for advanced or metastatic breast cancer |
| Q36962531 | Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells |
| Q39836265 | Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial |
| Q55070923 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. |
| Q33861915 | Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism |
| Q37355729 | Lapatinib: new opportunities for management of breast cancer |
| Q38844243 | Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization |
| Q34241118 | Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib |
| Q38080673 | Mechanisms of TKI-induced diarrhea in cancer patients |
| Q28730745 | Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study |
| Q35002433 | Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib |
| Q38427102 | Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. |
| Q36455404 | Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors |
| Q39683562 | Modulation of P-gp expression by lapatinib. |
| Q37683112 | Molecular alterations in uterine serous carcinoma |
| Q41712860 | Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer |
| Q37787577 | Moving towards dose individualization of tyrosine kinase inhibitors |
| Q52876533 | Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells. |
| Q36485355 | Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer |
| Q33841512 | New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis |
| Q36262855 | Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation |
| Q41561954 | Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. |
| Q24293022 | Oncogenic ERBB3 mutations in human cancers |
| Q86952613 | Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer |
| Q64934294 | Personalized medicine in breast cancer: pharmacogenomics approaches. |
| Q35911350 | Personalized therapy in endometrial cancer: Challenges and opportunities |
| Q33735413 | Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens |
| Q36505700 | Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence |
| Q42595256 | Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. |
| Q35284749 | Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation |
| Q38838757 | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment |
| Q35544606 | Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling |
| Q38048814 | Primary systemic therapy in HER2-amplified breast cancer: a clinical review |
| Q37736390 | Proteogenomic integration reveals therapeutic targets in breast cancer xenografts |
| Q33638654 | Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status |
| Q37473177 | Renal toxicity of targeted therapies |
| Q28384553 | Reverse phase protein microarrays advance to use in clinical trials |
| Q38678038 | Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials |
| Q44692841 | Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies |
| Q58788266 | Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors |
| Q34417920 | Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. |
| Q64056219 | STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review |
| Q23923997 | Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting |
| Q35222776 | Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine |
| Q37906461 | Stem cell MicroRNAs in senescence and immortalization: novel players in cancer therapy |
| Q35116206 | Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors |
| Q91599776 | Synthesis of 2-alkylthio-N-(quinazolin-2-yl)benzenesulfonamide derivatives: anticancer activity, QSAR studies, and metabolic stability |
| Q37763156 | Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise |
| Q38114062 | Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma |
| Q35553821 | Targeted endoscopic imaging |
| Q90862850 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer |
| Q42571051 | Targeted therapy in HER2-positive breast cancer |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q38194548 | Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib |
| Q36280842 | Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. |
| Q34246558 | Targeting the EGFR signaling pathway in cancer therapy |
| Q44503403 | The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse |
| Q37312071 | The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells |
| Q36771985 | The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells |
| Q36171144 | The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q49887915 | The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer |
| Q50854840 | Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance |
| Q54482784 | Tosylate salts of the anticancer drug lapatinib. |
| Q28074691 | Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma |
| Q35566231 | Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers |
| Q55041848 | Trastuzumab is not a tyrosine kinase inhibitor. |
| Q30458767 | Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors |
| Q37981002 | Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations |
| Q92324352 | Utilizing gastric cancer organoids to assess tumor biology and personalize medicine |
| Q34214918 | X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor |
| Q36269777 | Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer |
Search more.